I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES OF THE TRIAL
Primary objective
Evaluation of efficacy in terms of progression-free survival at 9 months of the combination
of intensified methotrexate, vinblastine, doxorubicin and cisplatin with or without
panitumumab as first-line treatment of advanced urothelial carcinoma in patients without
Harvey nor Kirsten rat sarcoma viral oncogene homolog mutations.
Secondary objectives
- To assess toxicity
- To assess response rate
- To assess overall survival
- To assess time to progression
- To study the correlation between response rate, time to progression, overall survival
and biological parameters